Antimicrobial susceptibility patterns of 112 clinical isolates, 28 type strains, and 9 reference strains of Nocardia were determined using the Sensititre Rapmyco microdilution panel (Thermo Fisher, Inc.). Isolates were identified by highly discriminatory multilocus sequence analysis and were chosen to represent the diversity of species recovered from clinical specimens in Ontario, Canada. Susceptibility to the most commonly used drug, trimethoprim-sulfamethoxazole, was observed in 97% of isolates. Linezolid and amikacin were also highly effective; 100% and 99% of all isolates demonstrated a susceptible phenotype. For the remaining antimicrobials, resistance was species specific with isolates of Nocardia otitidiscaviarum, N. brasiliensis, N. abscessus complex, N. nova complex, N. transvalensis complex, N. farcinica, and N. cyriacigeorgica displaying the traditional characteristic drug pattern types. In addition, the antimicrobial susceptibility profiles of a variety of rarely encountered species isolated from clinical specimens are reported for the first time and were categorized into four additional drug pattern types. N ocardia species are a group of filamentous, branching, Grampositive, modified-acid-fast bacilli that normally exist as soil saprophytes but can cause disease in immunosuppressed and healthy individuals (1). Most infections involve inhalation of fragments of filaments, resulting in pulmonary nocardiosis and pneumonia, which can be followed by dissemination to the heart, skin, subcutaneous tissue, and central nervous system (1).
N ocardia species are a group of filamentous, branching, Grampositive, modified-acid-fast bacilli that normally exist as soil saprophytes but can cause disease in immunosuppressed and healthy individuals (1) . Most infections involve inhalation of fragments of filaments, resulting in pulmonary nocardiosis and pneumonia, which can be followed by dissemination to the heart, skin, subcutaneous tissue, and central nervous system (1) .
Nocardia taxonomy has been linked to specific patterns of antimicrobial susceptibility ever since the foundational work by Wallace et al. (2) established the presence of six drug pattern types among the Nocardia asteroides species complex. Subsequent research linked the drug pattern types with the following Nocardia species: N. abscessus, drug pattern type I; N. brevicatena/paucivorans complex, drug pattern type II; N. nova complex, drug pattern type III; N. transvalensis complex, including N. wallacei and N. blacklockiae, drug pattern type IV; N. farcinica, drug pattern type V; and N. cyriacigeorgica, drug pattern type VI (1, 3) . Together with N. brasiliensis and N. otitidiscaviarum, N. abscessus, N. nova, N. farcinica, and N. cyriacigeorgica are frequently associated with clinical infections (2, 4) . With the clinical application of DNA sequencing, Nocardia taxonomy has changed and expanded rapidly. Previously identified species have been reclassified as species complexes encompassing multiple species, and numerous novel Nocardia species have been identified (5) . Currently, 87 species are enumerated in the List of Prokaryotic Names with Standing in Nomenclature (LPSN) (http://www.bacterio.net/nocardia.html), many of which are clinically significant (1) .
However, data on antimicrobial susceptibility has lagged behind the advances in taxonomy, with only a few reports providing recent data on newer antimicrobials (4, 6, 7, 8, 9, 10, 11, 12, 13) . These reports largely focus on the species traditionally associated with clinical infections, such that antimicrobial susceptibility data are not available for a large number of newly identified, but clinically relevant, Nocardia species that are isolated less frequently in the clinical laboratory. Furthermore, the species in these studies were identified using microscopy and biochemical testing, or the identification relied heavily on the 16S rRNA gene sequence analysis, both of which are unable to reliably discriminate many Nocardia species (5, 14, 15) .
The purpose of this study was to profile the antimicrobial susceptibility patterns of a diverse range of Nocardia species isolated from clinical specimens. Unlike the previous studies, all isolates were identified with a high degree of confidence and discrimination using multilocus sequence analysis (MLSA) (5) . Thus, we provide a timely update on the antimicrobial susceptibility patterns of the species frequently isolated from clinical specimens, such as N. brasiliensis, N. otitidiscaviarum, N. abscessus complex, N. nova complex, N. farcinica, and N. cyriacigeorgica, and detail novel data on the antimicrobial susceptibility of a variety of rarely encountered species. Additionally, the antimicrobial susceptibility testing (AST) was performed using the commercial Sensititre Rapmyco microdilution panel (Thermo Fisher, Inc., Cleveland, OH, USA). We report robustly determined MIC values for three quality control (QC) strains to demonstrate the suitability of this product for the determination of antimicrobial susceptibility profiles of clinical isolates of Nocardia spp. and to facilitate the validation and implementation of this method in other clinical laboratories.
MATERIALS AND METHODS
A total of 112 clinical isolates, 28 type strains, and 9 reference strains were previously identified to the species level by MLSA. Briefly, partial sequences of five loci, including genes for gyrase B, the ␤-subunit of DNA topoisomerase (gyrB) (482 bp), 16S rRNA (16S) (462 bp), subunit A of SecA preprotein translocase (secA1) (445 bp), 65-kDa heat shock protein (hsp65) (400 bp), and RNA polymerase (rpoB) (400 bp), were concatenated and compared to sequences of 36 type and 11 reference strains. Using neighbor-joining phylogenetic analysis, we noted sequence clusters with Ͼ85% bootstrap support that each contained a single type strain in most cases. Therefore, identification of isolates was made according to their species cluster (5) . In all cases, the identifications provided by MLSA were consistent with (i.e., not discrepant) although often more discriminatory than those generated by the CLSI-recommended targets 16S and secA1 (16) , which were included in the MLSA.
The strains were selected to represent the diversity of Nocardia species isolated by the Mycology Section of the Ontario Public Health Laboratory, Public Health Ontario, from December 2005 through July 2011. Following revival from storage in 20% (wt/vol) glycerol at Ϫ80°C, isolates were subcultured twice on GYM Streptomyces medium (0.4% glucose, 0.4% yeast extract, 1% malt extract, 0.2% CaCO 3 , and 1.2% agar) agar plates and incubated at 37°C for 3 to 4 days prior to antimicrobial susceptibility testing. The type and reference strains included in this study are listed in Table S1 in the supplemental material.
AST of all isolates was determined by broth microdilution using the Sensititre Rapmyco microdilution panel (Thermo Fisher, Inc., Cleveland, OH, USA), according to CLSI M24-A2 guidelines (17, 18) and the manufacturer's instructions (amikacin, 1 to 64 g/ml; amoxicillin-clavulanic acid, 2/1 to 64/32 g/ml; cefepime, 1 to 32 g/ml; ceftriaxone, 4 to 64 g/ml; ciprofloxacin, 0.12 to 4 g/ml; clarithromycin, 0.03 to 16 g/ml; doxycycline, 2 to 64 g/ml; imipenem, 2 to 64 g/ml; linezolid, 1 to 32 g/ml; minocycline, 1 to 8 g/ml; moxifloxacin, 0.25 to 8 g/ml; tigecycline, 0.015 to 4 g/ml; tobramycin, 1 to 16 g/ml; and trimethoprimsulfamethoxazole [SXT], 0.25/4.75-8/152 g/ml). (Note: this panel has not received Food and Drug Administration clearance and is therefore designated for research use only, not for use in diagnostic procedures.) Cefoxitin (4 to 128 g/ml) is present on the panel but is not reported on as it has not been shown to be useful for Nocardia infections in vivo. There are no CLSI breakpoints for tigecycline, and clinical experience is limited with this antibiotic. However, it appears to have good in vitro activity against a number of Nocardia species and is therefore included in this study. In order to achieve a homogeneous suspension, an isolate was initially suspended in 200 l of sterile water and dispersed using a sterilized plastic disposable pestle (Kimble Chase, Vineland, NJ, USA). The suspension was adjusted to a 0.5 McFarland turbidity standard using a nephelometer, and 50 l was transferred to 10 ml of Mueller-Hinton broth. Each well of the panel was inoculated with 100 l of the Mueller-Hinton broth. MIC values were interpreted as susceptible (S), intermediate (I), or resistant (R) according to the CLSI (18) after 48 to 72 h of incubation at 37°C when moderate growth was observed in the positive-control well. Four isolates (N. transvalensis NRRL B-10637, N. exalbida DSM 44883, N. gamkensis DSM 44956, and a clinical isolate of N. anaemiae) required 96 h of incubation before the positive-control well exhibited acceptable growth. For these isolates, MIC values were determined at 96 h; however, imipenem results were not recorded due to its instability noted by us and others (19) .
N. nova ATCC BAA-2227 (incubated for 72 h), N. asteroides ATCC 19247
T (incubated for 72 h), and N. farcinica ATCC 23826 (incubated for 48 h) (American Type Culture Collection, Manassas, VA, USA) were chosen as quality control organisms with antimicrobial susceptibility determined by a series of 20 independent trials conducted on 20 separate days over a period of 2 months (17, 18) .
RESULTS
The MIC values for the control strains N. nova ATCC BAA-2227, N. asteroides ATCC 19247 T , and N. farcinica ATCC 23826 demonstrated a high degree of reproducibility and strong correlation with published data on resistance profiles of the three strains (14, 20, 21) ( Table 1 ). The data indicate that the Sensititre Rapmyco microdilution panel is suitable for the routine determination of the antimicrobial resistance patterns of Nocardia spp. in the clinical laboratory.
Using the Sensititre Rapmyco panel, we determined antimicrobial susceptibility profiles for 149 Nocardia isolates. All isolates were previously identified with a high degree of confidence and discrimination using MLSA (5) and were selected to represent the spectrum of species recovered from clinical specimens in Ontario, Canada, including both those that are traditionally recognized as clinically relevant and those that are rarely encountered. The percentage of susceptible isolates for each of the antibiotics for each of the species or species complexes is listed in Table 2. MIC ranges,  MIC 50 values, and MIC 90 values are available in Tables S2, S3 , and S4 in the supplemental material. Linezolid, amikacin, and SXT were the most effective antimicrobials with 100%, 99%, and 97%, respectively, of Nocardia isolates demonstrating susceptibility (Table 2) . For the tetracyclines, none of the isolates were resistant to minocycline and only 11% were resistant to doxycycline; however, the rates of intermediate resistance were high at 39% and 52%, respectively (Table 2 ). For the remaining antimicrobials, substantial numbers of Nocardia isolates were resistant, and resistance was species specific (Table 2) .
DISCUSSION
The CLSI guidelines recommend broth microdilution for the determination of the antimicrobial susceptibility of Nocardia spp. (18) . While in-house prepared panels are specified in that document, we have demonstrated the suitability of the Sensititre Rapmyco microdilution panel for the determination of antimicrobial susceptibility patterns of clinical isolates of Nocardia spp. MIC values for the three control strains, N. nova ATCC BAA-2227, N. asteroides ATCC 19247 T , and N. farcinica ATCC 23826, were highly reproducible and correlated well with expected resistance profiles (7, 20, 21) . The MIC values are published here to assist other clinical laboratories in implementing quality control guidelines for the validation of Nocardia antimicrobial susceptibility testing assays using this commercial panel.
The reproducibility of the broth microdilution method for antimicrobial susceptibility testing of Nocardia species was recently demonstrated by Conville and colleagues (7) in a multisite study using panels custom made by Thermo Fisher, Inc. (Cleveland, OH). Prior to this study, non-Nocardia, rapidly growing bacteria were recommended as QC strains for susceptibility testing, despite their very different growth characteristics during susceptibility testing. As an outcome of the work of Conville et al. (7) , N. nova ATCC BAA-2227 was recommended as the Nocardia reference strain for antimicrobial susceptibility testing of Nocardia spp. Our testing of N. nova ATCC BAA-2227 showed that not only were our results reproducible over 20 repeat tests but we also obtained MICs that were within the mode Ϯ 1 dilution for all antimicrobials tested in the Conville et al. study (7) , except for two drugs (amikacin and imipenem) where the Sensititre Rapmyco panel did not include dilutions as low as those on the in-house study panel. For all but one drug, we obtained the identical interpretive call as the expected interpretation established in the Conville et al. study (7) . The one exception was moxifloxacin, where our MIC mode was one dilution lower than their MIC mode, resulting in an "intermediate" interpretation by us and a "resistant" interpretation by Conville et al. (7), which is defined as a minor interpretive error (7). However, they also noted a substantial number (38.1%) of tests with an intermediate interpretation (7) . These results indicate that the Sensititre Rapmyco panel is equivalent to custommade panels prepared according to the CLSI guidelines (18) . Beyond validation, the Sensititre Rapmyco panels were used to assess a set of Nocardia isolates well characterized by MLSA in order to provide a comprehensive update on the antimicrobial susceptibility patterns of the most diverse set of species to date, including those that are traditionally recognized and many that are rarely encountered in a clinical setting. Trimethoprim-sulfamethoxazole (SXT) is the usual drug of choice for the treatment of Nocardia infections, making surveillance of SXT suscep- Table 2 ). The level of SXT resistance reported in the literature varies widely. Similar to our results, some studies report high levels of susceptibility (Ͼ90% of isolates) to SXT (4, 6, 8, 10, 22) ; however, others report significant levels of resistance ranging from 21% to 43% of isolates tested (9, 12, 13) . Possible reasons for the discrepancy include geographic differences, possible exposure to SXT as a result of patient treatment prior to testing (4), questionable reproducibility of in-house prepared panels, and, until recently, the lack of standardized testing methodologies and well-characterized QC strains. Unsatisfactory reproducibility of SXT testing with N. farcinica and N. wallacei has been noted by others and attributed to the inherent growth characteristics of the species, problems with homogeneous inoculum preparation, and/or difficulty determining the MIC (7). However, consistent with our observation regarding the overall high susceptibility of Nocardia species to SXT, there are few literature reports of SXT treatment failure for Nocardia infections (4). The results suggest that in Ontario, Canada, SXT remains the recommended first-line therapeutic drug of choice for Nocardia infections. However, given the significant level of in vitro resistance noted in some studies, testing for susceptibility to SXT should be performed for isolates from clinically relevant infections, and SXT susceptibility should continue to be monitored. As noted by others (6, 8, 9, 10, 11, 12, 13, 22) , all of the Nocardia isolates were susceptible to linezolid and almost all were susceptible to amikacin except for some isolates of the N. transvalensis complex (Table 2 ). However, for many of the remaining antimicrobials, substantial numbers of Nocardia isolates were resistant, and resistance was species specific (Table 2) as noted in other studies (6, 7, 8, 9, 10, 11, 12, 13, 22, 23) . As previously described by Brown-Elliott et al. (1) and others (8, 9, 12, 13) , we noted a strong correlation between the drug pattern types of Wallace et al. (2, 21) and species identification (Table 3) , with type I, III, IV, V, and VI drug patterns displayed by the N. abscessus complex, N. nova complex, N. transvalensis complex, N. farcinica, and N. cyriacigeorgica, respectively. We did not have any clinical isolates of N. brevicatena/paucivorans (type II drug pattern). N. otitidiscaviarum and N. brasiliensis isolates also displayed distinct drug patterns and were numbered types VII and VIII, respectively (Table 3) . Some discrepancies were noted. In particular, Brown-Elliott et al. (1) and Wallace et al. (2) reported that the N. transvalensis complex was susceptible to imipenem, but we noted resistance among all isolates. Uhde et al. (13) also reported a high rate of resistance (52%) among their isolates. With respect to N. farcinica, Brown-Elliott et al. (1) and Wallace et al. (2) indicated that it is susceptible to imipenem and ciprofloxacin, while we and other investigators (8, 9, 12, 13) noted susceptibility only among approximately half of the isolates (Table 2 ). Unlike Brown-Elliott et al. (1) , who indicated that N. otitidiscaviarum isolates were susceptible to ciprofloxacin, we report them as largely nonsusceptible, as did Udhe et al. (13) (Table 2 ). These differences may be attributed to different geographic isolation or the evolution of drug resistance over the ϳ20 years between the original report by Wallace et al. (2) and more recent studies.
In addition to the antimicrobial susceptibility patterns of these well-recognized species, we also report preliminary antimicrobial susceptibility patterns for isolates of species that were not categorized within these traditionally acknowledged groups and yet were recovered from clinical specimens ( Table 2) . A limitation of our (5) . g N. transvalensis complex: contains strains of N. transvalensis and N. wallacei. h Consistent with the drug pattern type described by Brown-Elliott et al. (1) and assigned a number in this study.
